PDSB - PDS Biotech updates Phase 2 data for lead asset in head and neck cancer
2023-10-03 08:51:33 ET
More on PDS Biotech
- PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript
- PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
- The Prognosis For PDS Biotechnology
- PDS Biotech gains after updates on pivotal trial for lead asset
- Seeking Alpha’s Quant Rating on PDS Biotechnology
For further details see:
PDS Biotech updates Phase 2 data for lead asset in head and neck cancer